Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia

[1]  Daniel M. Johnstone,et al.  Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism – An abscopal neuroprotective effect , 2014, Neuroscience.

[2]  Daniel M. Johnstone,et al.  Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. , 2014, Journal of neurosurgery.

[3]  Daniel M. Johnstone,et al.  Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex – evidence from two transgenic mouse models , 2014, Alzheimer's Research & Therapy.

[4]  U. Oron,et al.  Long-term safety of low-level laser therapy at different power densities and single or multiple applications to the bone marrow in mice. , 2013, Photomedicine and laser surgery.

[5]  A. Ennaceur,et al.  Non-invasive infra-red therapy (1072 nm) reduces β-amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. , 2013, Journal of photochemistry and photobiology. B, Biology.

[6]  Daniel M. Johnstone,et al.  Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains , 2013, BMC Neuroscience.

[7]  Tianhong Dai,et al.  Transcranial Low-Level Laser Therapy Improves Neurological Performance in Traumatic Brain Injury in Mice: Effect of Treatment Repetition Regimen , 2013, PloS one.

[8]  J. Stone,et al.  Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. , 2012, Parkinsonism & related disorders.

[9]  J. Stone,et al.  Patterns of Cell Activity in the Subthalamic Region Associated with the Neuroprotective Action of Near-Infrared Light Treatment in MPTP-Treated Mice , 2012, Parkinson's disease.

[10]  Michael R Hamblin,et al.  Low‐Level Laser Therapy for Closed‐Head Traumatic Brain Injury in Mice: Effect of Different Wavelengths , 2012, Lasers in surgery and medicine.

[11]  F Gonzalez-Lima,et al.  Low-level light therapy of the eye and brain. , 2011, Eye and brain.

[12]  Riccardo Natoli,et al.  Gene and noncoding RNA regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina , 2010, Molecular vision.

[13]  J. Kril,et al.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models , 2010, Proceedings of the National Academy of Sciences.

[14]  Jürgen Götz,et al.  Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.

[15]  B. Ivandic,et al.  Low-level laser therapy improves vision in patients with age-related macular degeneration. , 2008, Photomedicine and laser surgery.

[16]  A. Benabid,et al.  Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. , 2007, Brain : a journal of neurology.

[17]  Marc Fisher,et al.  Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.

[18]  Amir Oron,et al.  low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. , 2007, Journal of neurotrauma.

[19]  Jieli Chen,et al.  Low-Level Laser Therapy Applied Transcranially to Rats After Induction of Stroke Significantly Reduces Long-Term Neurological Deficits , 2006, Stroke.

[20]  Ottavio Arancio,et al.  Progressive age‐related development of Alzheimer‐like pathology in APP/PS1 mice , 2004, Annals of neurology.

[21]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[22]  Noel T. Whelan,et al.  Therapeutic photobiomodulation for methanol-induced retinal toxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[24]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[25]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[26]  Hans Lassmann,et al.  Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.

[27]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[28]  H. Braak,et al.  Alzheimer's disease: amyloid plaques in the cerebellum , 1989, Journal of the Neurological Sciences.

[29]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[30]  Bradley T. Hyman,et al.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease , 2014, Acta Neuropathologica.

[31]  Luis De Taboada,et al.  Transcranial laser therapy attenuates amyloid-β peptide neuropathology in amyloid-β protein precursor transgenic mice. , 2011, Journal of Alzheimer's disease : JAD.

[32]  Keyoumars Ashkan,et al.  Neuroprotection of midbrain dopaminergic cells in MPTP‐treated mice after near‐infrared light treatment , 2010, The Journal of comparative neurology.